Page 4 - அலெக்ஸாண்ட்ரியா துணிகர முதலீடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Axonis Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company advancing breakthrough research to develop therapies for neurological disorders, secured an additional $5m in funding. The round was led by Alexandria Venture Investments with participation from R3 Bio, BoxOne Ventures and Civilization Ventures and the Christopher & Dana Reeve Foundation and Spinal Research. The company intends to use the funds to advance its novel neuromodulating technology into the clinic. Led by Joanna Stanicka, PhD, CEO, and Shane Hegarty, PhD, Chief Scientific Officer, Axonis Therapeutics is advancing breakthrough research to develop therapies for neurological disorders. The company’s pipeline includes neuron-reviving therapeutics that enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration, restore excitation/inhibition balance and regenerate. The company’s targeted indications include spinal cord injury and epilepsy, as well as broader neurodeg

United kingdomAl iskandariyahJoanna stanickaShane hegartyAxonis therapeutics incChristopher dana reeve foundationAxonis therapeuticsAlexandria venture investmentsBoxone venturesCivilization venturesDana reeve foundationChief scientific officerஒன்றுபட்டது கிஂக்டம்ஷேன் ஹெகார்டிகிறிஸ்டோபர் டானா ரீவ் அடித்தளம்அலெக்ஸாண்ட்ரியா துணிகர முதலீடுகள்